Ublituximab: Completed Ph III GENUINE enrollment

TG Therapeutics completed enrollment of 120 patients in the open-label, U.S. Phase III GENUINE trial comparing IV ublituximab on days 1, 8 and 15 followed by maintenance doses plus once-daily oral Imb...